Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glpg0492. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glpg0492 SCHEMBL2021011 | 1.00 | AR (0.74) | ARPGR | |
| Glpg0492 SCHEMBL2024404 | 1.00 | AR (0.74) | ARPGR | |
| SCHEMBL1712079 | 0.93 | AR (0.73) | ARPGR | |
| SCHEMBL1712370 | 0.91 | AR (0.62) | ARPGR | |
| SCHEMBL1712106 | 0.91 | AR (0.62) | ARPGR | |
| SCHEMBL1967769 | 0.91 | AR (0.74) | ARPGR | |
| SCHEMBL16683701 | 0.91 | AR (0.74) | ARPGR | |
| SCHEMBL3491965 | 0.91 | AR (0.62) | ARPGR | |
| SCHEMBL1712726 | 0.91 | AR (0.64) | ARPGR | |
| SCHEMBL1712737 | 0.91 | AR (0.64) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344460-B1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS INC (US) | 2015-08-12 | — | — | EP | claimed |
| CN-102149687-B | Novel imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV | 2014-08-13 | — | — | CN | claimed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | claimed |
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2012-07-12 | — | — | US | claimed |
| EP-2344460-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Galapagos N.V. (BE) | 2011-07-20 | — | — | EP | claimed |
| US-7968581-B2 | Imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV (BE) | 2011-06-28 | — | — | US | claimed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | claimed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | claimed |
| EP-2344460-B1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-102149687-B | Novel imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV | 2014-08-13 | — | — | CN | disclosed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | disclosed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | disclosed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | disclosed |
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-7968581-B2 | Imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | AR 1/4885PGR 226/4885 |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | AR 1/4885PGR 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.